研究概要
本研究鉴定了胃癌免疫耐药的潜在细胞和分子决定因素,并提出靶向该 T/NK 细胞亚群或恢复 IRF1 功能是值得进一步探索、以克服 ICI 耐药的有前景的策略。
中文摘要
免疫检查点抑制剂耐药是胃癌治疗中的重大临床障碍,识别耐药细胞群及其标志物仍是亟待解决的问题。本研究构建胃癌单细胞转录组图谱,发现一类与免疫检查点抑制剂(ICI)耐药相关的T/NK细胞亚群。这些细胞与肿瘤细胞之间经MHC-I介导的免疫识别受损,处于T细胞分化早期阶段,并表现出组氨酸代谢增强。机制研究确定转录因子IRF1可能抑制胃癌免疫耐药。基于这些发现,研究建立了可有效预测患者免疫治疗应答的机器学习模型。值得注意的是,该模型在两个独立队列中均具有合理的预测表现(AUC分别为0.75和0.73)。体外实验进一步证实,IRF1可抑制癌细胞侵袭并促进凋亡。总之,本研究确定了胃癌免疫耐药的潜在细胞和分子决定因素,并提示靶向该T/NK细胞亚群或恢复IRF1功能,可能是值得进一步探索的克服ICI耐药策略。
展开英文摘要原文
Resistance to immune checkpoint inhibitors is a major clinical obstacle in the treatment of gastric cancer. Identifying drug-resistant cell populations and markers remains an urgent problem to be solved. This study by constructing a single-cell transcriptomic atlas of gastric cancer, we identified a subset of T/NK cells associated with ICI resistance. These cells exhibited impaired MHC-I-mediated immune recognition with tumor cells, were positioned at an early stage of T cell differentiation, and displayed elevated histidine metabolism. Mechanistically, we identified the transcription factor IRF1 as a potential suppressor of immune resistance in gastric cancer. Building on these findings, we developed a machine learning model that effectively predicts patient responses to immunotherapy. Notably, the model predicted responses reasonably well across two independent cohorts (AUCs 0.75 and 0.73). In vitro experiments further demonstrated that IRF1 inhibits cancer cell invasion and promotes apoptosis. In summary, this study identifies potential cellular and molecular determinants of immune resistance in gastric cancer and suggests that targeting this T/NK cell subset or restoring IRF1 function represents a promising strategy worth further exploration to overcome ICI resistance.
论文信息
- 作者
- Ning W、Su Y、Hou Y、Zhang XY、Liu ZW、Yang CB
- 单位
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, The Fourth Military Medical University, Xi'an, China710032.China
- 期刊
- Journal of chemical information and modeling2026 Aug 10